Potential of topical norfloxacin therapy. Comparative in vitro activity against clinical ocular bacterial isolates

Arch Ophthalmol. 1987 Jul;105(7):991-4. doi: 10.1001/archopht.1987.01060070135043.


Norfloxacin, a new fluoroquinolone antibiotic related to nalidixic acid, was evaluated as a topical agent for clinical efficacy in bacterial eye infections. This study reports on the comparative in vitro activity of norfloxacin and ten topical antibiotics (nalidixic acid, polymyxin B, colistin, bacitracin, chloramphenicol, sulfamethoxazole, tetracycline, erythromycin, gentamicin, and tobramycin) against 203 pathogenic eye isolates of 17 genera (37 species). In general, norfloxacin had the greatest potency and broadest spectrum of activity of the agents tested. It was active against Staphylococcus aureus (minimal inhibitory concentration against 90% [MIC90], less than or equal to 1.0 microgram/mL), coagulase-negative staphylococci (MIC90, less than or equal to 1.0 microgram/mL), Pseudomonas aeruginosa (MIC90, less than or equal to 1.0 microgram/mL), and Haemophilus organisms (MIC90, less than or equal to 1.0 microgram/mL).

Publication types

  • Comparative Study

MeSH terms

  • Administration, Topical
  • Bacterial Infections / drug therapy
  • Bacterial Infections / microbiology*
  • Eye Diseases / drug therapy
  • Eye Diseases / microbiology*
  • Humans
  • In Vitro Techniques
  • Microbial Sensitivity Tests
  • Norfloxacin / administration & dosage
  • Norfloxacin / pharmacology*


  • Norfloxacin